2024 Phergain study

Phergain study

Author: cjas

August undefined, 2024

WebEssais cliniques pour trastuzumab emtansin. Registre des essais cliniques. ICH GCP. WebThe PHERGain trial had two groups, or arms, discussed at the 2024 ASCO Annual Meeting. In the control arm, the group that got standard treatment, 71 people got chemotherapy …

A phase II study of palbociclib plus letrozole plus trastuzumab as ...

WebJul 12, 2024 · PARP inhibitors (PARPi), olaparib and talazoparib, are indicated in patients with HER2-negative advanced breast cancer with germline BRCA1/2 mutations. Preclinical data have demonstrated an interaction between DNA damage induced by PARPi and the immune system. WebAll patients who received at least one cycle of therapy were assessed for safety. This trial is registered with ClinicalTrials.gov, number NCT02530424. The trial is ongoing and two further cohorts are being enrolled. Findings: Thus, 35 patients were included in safety analyses and 30 were assessed for the primary and secondary endpoints. marie taccogna

Chemotherapy de-escalation using an 18 F-FDG-PET-based

WebFeb 1, 2024 · Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) The safety and scientific … WebThe PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 ( ClinicalTrials.gov ) View Download 21 Reads... WebMay 19, 2024 · (PHERGain) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT03161353 Recruitment Status : Active, not recruiting dali o\u0027neill

Phergain study

WebSep 8, 2024 · In the PHERGAIN trial, researchers showed that early evaluation of metabolic response using 18F-FDG PET/CT could help identify patients who will develop a pathologic complete response (pCR) to dual HER2 blockade alone, potentially allowing them to avoid chemotherapy [1]. WebMay 29, 2024 · PHERGAIN In another trial, researchers showed that early evaluation of metabolic response using 18 F-FDG PET/CT could help identify patients who will develop a pCR to dual HER2 blockade alone, potentially …

Did you know?

WebJun 4, 2024 · The study authors noted that neoadjuvant dual blockade of HER2 results in pathologic complete response (pCR) rates of up to 36.3%, which provides rationale for … WebJun 14, 2010 · Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2024;29(3):646-653. doi:10.1093/annonc/mdx773 PubMedGoogle …

WebJan 6, 2024 · The PHERGain study evaluating de-escalating neoadjuvant therapy in patients with HER2+ breast cancer demonstrated a pCR rate of 32.3% in patients with ER+/HER2+ early breast cancer treated with ... WebMay 19, 2024 · The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary …

WebThe definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these … WebJun 10, 2024 · The addition of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)–positive breast cancer. However, 15%-31% of patients still develop disease recurrence, on the basis of long-term follow-up of adjuvant pivotal trials. A better understanding of tumor biology has led …

WebFeb 1, 2024 · Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms ... (PHERGAIN-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

WebFeb 9, 2024 · • The PHERGain II clinical trial aims to demonstrate the viability of a non-chemotherapy alternative for treating those patients who can achieve a similar response … dalio torontoWebMay 1, 2024 · In the recently published PHERGAIN study [36], early metabolic response by FDG-PET showed promise to identify patients who will benefit from anti-HER2 therapy and, therefore, can be spared of ... marieta chavezWebMay 25, 2024 · PHERGain assessed early metabolic response by F-PET to neoadjuvant HP and the opportunity of CT de-escalation with a response-adapted strategy in patients … marieta catalaWebJun 14, 2010 · The TRYPHAENA study showed data only for an LVEF decline of 10% to less than 50% and symptomatic left ventricular systolic dysfunction and found no substantial … marieta cazarreWebJun 3, 2024 · PHERGain study Early results have shown that interim PET seems to be surrogate marker for pCR and the BCS rates are not compromised in the chemo free strategy and also with a favourable toxicity profile. Hence, a PET-adapted approach seems to be a promising modality for escalation, de-escalation strategy. marie tachell arizonaWebJun 19, 2024 · The PHERGAIN study is evaluating the use of positron emission tomography (PET) imaging during neoadjuvant therapy to monitor tumor response in patients with HER2-positive breast cancer. In preliminary results, investigators reported that patients whose PET scan showed positive response to the treatment had pathological complete response. dalio videoWebFeb 24, 2024 · PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer. The PHERGain II trial will investigate the treatment … marieta c atienza